| 1 |
34929424 | Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. | 2022 Feb |
1 |
| 2 |
35448200 | Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations. | 2022 Apr 15 |
2 |
| 3 |
34938186 | Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review. | 2021 |
1 |
| 4 |
32497289 | Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. | 2020 Aug |
1 |
| 5 |
27998448 | [Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients]. | 2016 Nov 23 |
1 |
| 6 |
24457564 | The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. | 2014 Mar |
1 |
| 7 |
24526178 | BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. | 2014 Apr |
1 |
| 8 |
25414026 | Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers. | 2014 Dec |
1 |
| 9 |
23881989 | Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. | 2013 |
1 |
| 10 |
22330686 | The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. | 2012 Feb 14 |
1 |
| 11 |
21157449 | Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. | 2011 Jan 18 |
1 |
| 12 |
20047843 | Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. | 2010 Sep |
1 |
| 13 |
20164691 | Triple-negative breast cancer: role of specific chemotherapy agents. | 2010 Jan-Feb |
1 |
| 14 |
19519295 | Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy? | 2009 Jun |
3 |
| 15 |
18798071 | PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance. | 2008 Dec |
1 |
| 16 |
19765269 | Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers. | 2007 |
1 |
| 17 |
16632419 | From the bench to the bed: individualizing treatment in non-small-cell lung cancer. | 2006 Feb |
1 |
| 18 |
16739340 | Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. | 2006 Jan-Feb |
1 |
| 19 |
16765644 | Predicting the outcome of chemotherapy for lung cancer. | 2006 Aug |
1 |